<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622815</url>
  </required_header>
  <id_info>
    <org_study_id>AIRC5xmille - 12237</org_study_id>
    <nct_id>NCT02622815</nct_id>
  </id_info>
  <brief_title>Hypercoagulation Screening in Cancer</brief_title>
  <acronym>HYPERCAN</acronym>
  <official_title>Hypercoagulation Screening as Innovative Tool for Risk Assessment, Early Diagnosis and Prognosis in Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Associazione Italiana per la Ricerca sul Cancro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Neurologico Mediterraneo Neuromed S. R. L</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Humanitas per la Ricerca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Sanitaria Locale Roma E</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituti Ospedalieri Bergamaschi Srl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Treviglio - Caravaggio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a complex, mutual relationship between cancer and thrombosis. Indeed, the tumor has
      the capacity to activate the hemostatic system and this leads to an increased thrombotic risk
      in cancer patients. Even in the absence of clinical manifestations, cancer patients are
      commonly characterized by hemostatic abnormalities, recognized only by laboratory testing,
      which define the 'hypercoagulable state'. Of interest, hypercoagulation has been repeatedly
      reported to be associated with tumor progression and poor prognosis in various carcinomas. On
      the other hand, thrombotic event can represent the first signal of the presence of an occult
      tumor. These findings suggest that the coagulant pathway might play a role in the preclinical
      phase of cancer. The investigators hypothesize that a persistent, subclinical activation of
      the hemostatic system in an otherwise healthy subject, may predispose not only to thrombosis,
      but also to tumor formation and spreading. A major problem in primary cancer prevention is
      the lack of effective predictive markers of the disease. The HYPERCAN is an ongoing
      prospective Italian multicenter study organized around two tightly-interconnected research
      programs aiming to: 1_the assessment of thrombotic markers as a tool for cancer risk
      prediction in two large populations of healthy subjects, i.e. a group of healthy blood donors
      of Bergamo and Milano Provinces and a subgroup of Moli-sani subjects of the Molise region;
      and 2_ the evaluation whether thrombotic markers and/or the occurrence of overt thrombosis
      (or disseminated intravascular coagulation) may be prognostic of cancer disease outcomes
      (i.e. overall survival, progression free survival in metastatic cancer, disease free survival
      in limited disease) in cancer patients with different types of solid tumors (i.e. breast,
      lung and gastrointestinal cancers).

      Therefore, the assessment of cancer risk occurrence in healthy individuals might be useful
      for anticipation of cancer diagnosis. In addition, the results of this study might help to
      evaluate whether thrombotic markers may be prognostic of cancer outcomes independently of the
      disease extension.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of blood donors with a diagnosis of cancer</measure>
    <time_frame>within 5 years from the date of the enrollment</time_frame>
    <description>Samples collected from identified participants with cancer diagnosis will be assessed to determine the hypercoagulation profile (ratio for laboratory analysis cancer case : healthy control from same cohort = 1:3, matched for age and gender)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Thrombotic events among enrolled cancer patients</measure>
    <time_frame>within 5 years from the date of the enrollment</time_frame>
    <description>Identification of cancer patients with evidence of thrombotic event derived from review of clinical records.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cancer progression among enrolled cancer patients</measure>
    <time_frame>within 5 years from the date of the enrollment</time_frame>
    <description>Identification of cancer patients with evidence of cancer progression derived from review of clinical records.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">16000</enrollment>
  <condition>Healthy Blood Donors</condition>
  <condition>Moli-sani Subjects</condition>
  <condition>Cancer Patients</condition>
  <arm_group>
    <arm_group_label>Healthy blood donors</arm_group_label>
    <description>10,000 highly controlled blood donors in the age range 35-65 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moli-sani subjects</arm_group_label>
    <description>A sample of 1,000 tumor cases have been identified so far and samples from these participants will be analyzed compared to 1,000 controls from randomly extracted from the Moli-sani cohort (parent cohort).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cancer patients</arm_group_label>
    <description>4,000 Patients with breast, lung, and gastrointestinal tumors.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, plasma, serum and tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Blood donors (age range 35-65 years), who agree to participate, fulfill a specific
        questionnaire on their lifestyle and donate venous blood samples at the enrolment into the
        study, and after 6-12 months.

        The parental cohort of the Moli-sani project included 24,325 subjects (&gt;35 years) from the
        Molise region. Blood samples have been collected and stored in the Moli-sani biobank
        available to this project.

        Cancer patients of both genders (&gt;18 years) with new diagnosis of non small cell lung
        cancer, gastrointestinal tumors, and breast cancer are enrolled at different recruiting
        sites. Blood samples are collected at the enrollment and at specific time points during
        follow-up without interfering with clinical management.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Blood donors_

        Inclusion Criteria:

          -  good health

          -  signed informed consent.

        Exclusion Criteria: (considering 10-15 days from blood sampling)

          -  inflammations/infections/fever;

          -  recent vaccinations;

          -  recent surgery;

          -  anticoagulant therapy.

        Cancer patients_

        Inclusion Criteria:

          -  with life expectation higher than 3 months;

          -  patients with breast, lung or gastrointestinal tumors candidated for chemotherapy
             regimen;

          -  ECOG PS 0-2;

          -  adeguate bone marrow and renal function;

          -  signed informed consent.

        Exclusion Criteria:

          -  acute medical illness;

          -  terminal conditions or life expectancy less than 3 months;

          -  under low molecular weight heparin at therapeutic dosage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Falanga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Papa Giovanni XXIII - Recruiting</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Falanga, MD</last_name>
    <phone>+39-035.267.8597</phone>
    <email>annafalanga@icthic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituti Ospedalieri Bergamaschi S.r.l. - Policlinico San Marco</name>
      <address>
        <city>Osio Sotto</city>
        <state>Bergamo</state>
        <zip>24040</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea D'Alessio, MD</last_name>
      <email>dr.dalessio@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Treviglio-Caravaggio</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro Barni, MD</last_name>
      <email>sandro_barni@ospedale.treviglio.bg.it</email>
    </contact>
    <contact_backup>
      <last_name>Mara Ghilardi, MD</last_name>
      <email>mara.ghily@alice.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Istituto Neurologico Mediterraneo NEUROMED</name>
      <address>
        <city>Pozzilli</city>
        <state>Isernia</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Humanitas per la Ricerca</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Santoro, MD</last_name>
      <email>armando.santoro@cancercenter.humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Giovanna Masci, MD</last_name>
      <email>giovanna.masci@cancercenter.humanitas.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII - Oncology Unit</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Labianca, MD</last_name>
      <email>rlabianca@hpg23.it</email>
    </contact>
    <contact_backup>
      <last_name>Carlo Tondini, MD</last_name>
      <email>ctondini@hpg23.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII - S.I.M.T.</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Falanga, MD</last_name>
      <email>annafalanga@icthic.com</email>
    </contact>
    <contact_backup>
      <last_name>Carmen J. Tartari, PhD</last_name>
      <email>aircfalanga@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo De Braud, MD</last_name>
      <email>filippo.debraud@istitutotumori.mi.it</email>
    </contact>
    <contact_backup>
      <last_name>Luigi Celio, MD</last_name>
      <email>luigi.celio@istitutotumori.mi.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ASL Roma E - ACO San Filippo Neri</name>
      <address>
        <city>Rome</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giampietro Gasparini, MD</last_name>
      <email>gasparini.oncology@tiscali.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberta Sarmiento, MD</last_name>
      <email>roberta.sarmiento@yahoo.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>December 4, 2015</last_update_submitted>
  <last_update_submitted_qc>December 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>A.O. Ospedale Papa Giovanni XXIII</investigator_affiliation>
    <investigator_full_name>ANNA FALANGA</investigator_full_name>
    <investigator_title>Director of the Division of Immunohematology and Transfusion Medicine</investigator_title>
  </responsible_party>
  <keyword>Hypercoagulation</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Cancer Risk Assessment</keyword>
  <keyword>Cancer Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombophilia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

